BioCentury
ARTICLE | Company News

Isis to use Huntington's biomarkers from KineMed, CHDI

February 22, 2013 2:05 AM UTC

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) will use biomarkers from KineMed Inc. (Emeryville, Calif.) and the not-for-profit CHDI Foundation Inc. (New York, N.Y.) to develop an antisense therapeutic for Huntington's disease (HD). KineMed and the foundation are partnered to use KineMed's isotopic labeling and Dynamic Proteomics technology to investigate biomarkers of HD progression and as a tool to evaluate potential therapeutics. Isis said it gains access to the biomarkers through a 2007 deal with CHDI to discover and develop an antisense treatment for HD. ...